Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Interactive Brokers Group Inc. Class A Common Stock (IBKR) vs Novavax Inc (NVAX) Price & Performance

Interactive Brokers Group Inc. Class A Common StockTrade
Novavax IncTrade

Price performance (Past 24H)

Key statistics

Interactive Brokers Group Inc. Class A Common Stock vs Novavax Inc — how do they compare? Interactive Brokers Group Inc. Class A Common Stock trades at $87.63 (market cap $39.18B), while Novavax Inc trades at $12.1 (market cap $1.82B). The key difference: Interactive Brokers Group Inc. Class A Common Stock is far larger — about 21.5× Novavax Inc's market cap, and Interactive Brokers Group Inc. Class A Common Stock pays a 0.4% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Interactive Brokers Group Inc. Class A Common Stock for 0 Days and Novavax Inc for 59 Days on average.

IBKRNVAX
Market Cap
$39.18B$1.82B
Volume
2,996,5996,198,505
Sector
FinancialsHealth
52-Week High
$98.19$12.56
52-Week Low
$61.05$6.22
Typical Hold Time
0 Days59 Days
Enterprise Value
$31.48B$1.39B
Dividend Yield
0.4%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Interactive Brokers Group Inc. Class A Common Stock

No Aura AI signal available yet.

Novavax Inc

Novavax (NVAX) trades at $11.22, down 0.88% on the day, with a bullish technical signal from moving averages and a neutral RSI. The company reported strong revenue of $1.12 billion in 2025 and a net income of $440.30 million, but faces negative cash flow and a projected net loss for 2026. Recent news highlights its strategic pivot to a partnership-driven model using its Matrix-M adjuvant technology, with regulatory approvals for its updated COVID-19 vaccine in key markets.

The outlook for NVAX is mixed, with analyst consensus strongly favoring a buy rating (73.92%) but significant financial risks including negative equity, persistent cash burn, and volatile earnings. Investment opportunity lies in the successful execution of its licensing strategy and expansion into oncology, though execution risks and competitive pressures remain key concerns for shareholders.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

IBKR
100% Buy0% Sell
Avg holding period · 0 Days
NVAX
59% Buy41% Sell
Avg holding period · 59 Days

Top news

Latest headlines on both assets

About Interactive Brokers Group Inc. Class A Common Stock

Interactive Brokers operates an electronic brokerage platform for trading stocks, options, futures, currencies, and other assets. It also provides clearing and custody services.

Read more on IBKR →

About Novavax Inc

Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.

Read more on NVAX →